Citations

Showing 10 of 108119 citations.

Oropharyngeal histoplasmosis: a report of 10 cases
Pincelli, Thaís , Enzler, Mark J., Davis, Mike , Tande, Aaron J. , Comfere, Nneka I. , Bruce, Alison J., Pincelli, T , Tande, Aaron , Davis, M.

Mayo Clinic

Clinical and Experimental Dermatology | February 1, 2019 | Volume: 44 | Issue: 5 | Pages: e181-e188

10.1111/ced.13927 | PMID 30706506 Get It

Renal Replacement Therapy and Intermittent Catheterization Risk in Posterior Urethral Valves
McLeod, Daryl J. , Szymanski, Konrad M. , Gong, Edward M. , Granberg, Candace F. , Reddy, Pramod , Sebastião, Yuri V. , Fuchs, Molly E. , Gargollo, Patricio C. , VanderBrink, Brian A. , (PUMA), on behalf of the Pediatric Urology Midwest Alliance, Granberg, Candace, Gargollo, Patricio, Whittam, Benjamin M. , (PUMA), on behalf of the Pediatric Urology Midwest Alliance

Mayo Clinic

Pediatrics | February 1, 2019 | Volume: 143 | Issue: 3 | Pages: No page available

10.1542/peds.2018-2656 | PMID 30709926 Get It

OBJECTIVES: Posterior urethral valves predispose children to renal replacement therapy (RRT) and bladder dysfunction. Researchers of single-institutional series were unable to refine risk stratification because of rarity of the disease. We aimed to identify clinical variables associated with the risk of RRT and clean intermittent catheterization (CIC) in a large multicenter cohort study. METHODS: Children with posterior urethral valves born between 1995 and 2005 who were treated before 90 days of life at 5 children’s hospitals were retrospectively reviewed. Outcomes included RRT and recommendation for CIC. Predictors and outcomes were assessed by using survival analysis. RESULTS: A total of 274 patients were managed for a median of 6.3 years, and 42 progressed to RRT. On survival analysis, 16% progressed to RRT by 10 years of age. RRT varied by the serum nadir creatinine level in the first year of life (SNC1) (log-rank P < .001). After stratifying by the SNC1, the estimated risk of progressing to RRT by 10 years of age was 0%, 2%, 27%, and 100% for an SNC1 of <0.4, an SNC1 of 0.4 to 0.69, an SNC1 of 0.7 to 0.99, and an SNC1 of ≥1.0 mg/dL, respectively. CIC was recommended in 60 patients, which translated on survival analysis to a risk of 26% by 10 years of age. CONCLUSIONS: Risk of RRT and CIC recommendation increased with age. The SNC1 strongly predicted need for RRT. These results allow for both improved family counseling and the potential for more appropriate screening and intervention strategies for those identified in higher-risk groups.
The impact of gastroesophageal reflux disease symptoms in scleroderma: effects on sleep quality
Horsley‐Silva, Jennifer L. , Umar, Sarah B. , Vela, Marcelo F. , Griffing, W. Leroy , Parish, James M., DiBaise, John K. , Crowell, Michael D.

Mayo Clinic

Diseases of the Esophagus | February 1, 2019 | Volume: 32 | Issue: 5 | Pages: No page available

10.1093/dote/doy136 | PMID 30715227 Get It

Injury pattern recognition to discriminate competing causes of liver injury
Talaat, Nizar , Tillmann, Hans L

Mayo Clinic

Liver International | January 31, 2019 | Volume: 39 | Issue: 5 | Pages: 821-825

10.1111/liv.14056 | PMID 30703293 Get It

AbstractBackgroundCompeting causes of liver injury may be difficult to discriminate. Characterization of the typical phenotype of each injury defined by latency, time to improvement and biochemical pattern, could be helpful to identify the most likely of competing causes.MethodsLiver injury characteristics of both bortezomib‐associated drug‐induced liver injury (DILI) and hepatitis B virus (HBV) reactivation associated with bortezomib are derived from PubMed listed publications.ResultsBortezomib‐associated DILI has very short latency of days and AP is found elevated, while liver injury due to HBV reactivation occurs after several months of bortezomib therapy. Therefore, a patient's liver injury pattern occurring 3 months into bortezomib therapy should be attributed to HBV reactivation.DiscussionIdentification of liver injury characteristics for competing causes of liver injury can be helpful to identify the most likely cause and improve clinical outcome.
Paternalism, Privacy, and Participation: Cell Phones on the Brain Injury Rehabilitation Unit
Ripley, David L. , Russell, Mary E. , Bergquist, Thomas F. , Tarsney, Preya S. , Mukherjee, Debjani

Mayo Clinic

PM&R | January 31, 2019 | Volume: 11 | Issue: 1 | Pages: 76-82

10.1002/pmrj.12041 | PMID 30703292 Get It

Association of Intravitreal Anti–Vascular Endothelial Growth Factor Therapy With Risk of Stroke, Myocardial Infarction, and Death in Patients With Exudative Age-Related Macular Degeneration
Starr, Matthew R. , AbouChehade, Jackson E., Damento, Gena M., García, María Dolores Aguilar , Shah, Saumya M. , Hodge, David O. , Meissner, Irene, Bakri, Sophie J. , Iezzi, Raymond , García, María, Starr, Matthew R , Dalvin, Lauren A. , Garcia, Maria

Mayo Clinic

JAMA Ophthalmology | January 31, 2019 | Volume: 137 | Issue: 5 | Pages: 483

10.1001/jamaophthalmol.2018.6891 | PMID 30703203 Get It

Bacterial Cultures at the Time of Artificial Urinary Sphincter Revision Surgery in Clinically Uninfected Devices: A Contemporary Series
Ziegelmann, Matthew , Linder, Brian J. , Avant, Ross, Elliott, Daniel S. , Ziegelmann, Matthew J, Avant, Ross A, Linder, Brian J

Mayo Clinic

Journal of Urology | January 31, 2019 | Volume: 201 | Issue: 6 | Pages: 1152-1157

10.1097/ju.0000000000000102 | PMID 30707131 Get It

Adherence to Guideline-Directed Stroke Prevention Therapy for Atrial Fibrillation Is Achievable
Piccini, Jonathan P. , Xu, Haolin , Cox, Margueritte, Curtis, Anne B. , Fang, Margaret C. , McCabe, Pamela J. , Page, Robert L. , Turakhia, Mintu P. , Russo, Andrea M. , Knight, Bradley P. , Sidhu, Mandeep S. , Hurwitz, Jodie L. , Ellenbogen, Kenneth A. , Lewis, William R. , Knight, Bradley P , Turakhia, Mintu P , Matsouaka, Roland , Fonarow, Gregg C. , Butler, Javed , Desai, Nihar R. , Ellenbogen, Kenneth A

Mayo Clinic

Circulation | January 31, 2019 | Volume: 139 | Issue: 12 | Pages: 1497-1506

10.1161/circulationaha.118.035909 | PMID 30700141 Get It

Background: Efforts to improve prescription of oral anticoagulation (OAC) drugs in patients with atrial fibrillation have had limited success in improving guideline adherence. Methods: We evaluated adherence to the American College of Cardiology/American Heart Association performance measures for OAC in eligible patients with a CHA 2 DS 2 -VASc score ≥2 and trends in prescription over time in the American Heart Association’s Get With The Guidelines–AFIB (atrial fibrillation) registry. Adjusted associations with in-hospital outcomes were also determined. The cohort included 33 235 patients with a CHA 2 DS 2 -VASc score ≥2 who were admitted for atrial fibrillation and were enrolled at 115 sites between January 1, 2013, and September 31, 2017. Results: The median (25th, 75th percentile) age was 73 years (65, 81 years); 51% were female; and the median (25th, 75th percentile) CHA 2 DS 2 -VASc score was 4 (3, 5). At admission, 16 206 (59.5%) of 27 221 patients with a previous diagnosis of atrial fibrillation were taking OAC agents, and OAC drug use at admission was associated with a lower adjusted odds of in-hospital ischemic stroke (odds ratio, 0.38; 95% CI, 0.24–0.59; P <0.0001). At discharge, prescription of OAC in eligible patients (no contraindications) was 93.5% (n=25 499 of 27 270). In a sensitivity analysis, when excluding only strict contraindications (4.6%, n=1497 of 32 806), OAC prescription at discharge was 80.3%. OAC prescription at discharge was higher in those aged ≤75 years, men, those with heart failure, those with previous atrial fibrillation ablation, and those with rhythm control ( P <0.0001 for all). OAC use was lowest in Hispanic patients (90.2%, P <0.0001). Prescription of OAC at discharge in eligible patients improved over time from 79.9% to 96.6% ( P <0.0001). Conclusions: Among hospitals participating in the GWTG-AFIB quality improvement program, OAC prescription at discharge in eligible guideline-indicated patients increased significantly and improved consistently over time. These data confirm that high-level adherence to guideline-recommended stroke prevention is achievable.
Lumbar fusion involving the sacrum increases dislocation risk in primary total hip arthroplasty
Salib, Christopher G. , Reina, Nicolas , Perry, Kevin I. , Taunton, Michael J. , Berry, Daniel J. , Taunton, Michael J , Berry, Daniel J , Abdel, Matthew P.

Mayo Clinic

The Bone & Joint Journal | January 31, 2019 | Volume: 101-B | Issue: 2 | Pages: 198-206

10.1302/0301-620x.101b2.bjj-2018-0754.r1 | PMID 30700125 Get It

Aims Concurrent hip and spine pathologies can alter the biomechanics of spinopelvic mobility in primary total hip arthroplasty (THA). This study examines how differences in pelvic orientation of patients with spine fusions can increase the risk of dislocation risk after THA. Patients and Methods We identified 84 patients (97 THAs) between 1998 and 2015 who had undergone spinal fusion prior to primary THA. Patients were stratified into three groups depending on the length of lumbar fusion and whether or not the sacrum was involved. Mean age was 71 years (40 to 87) and 54 patients (56%) were female. The mean body mass index (BMI) was 30 kg/m2 (19 to 45). Mean follow-up was six years (2 to 17). Patients were 1:2 matched to patients with primary THAs without spine fusion. Hazard ratios (HR) were calculated. Results Dislocation in the fusion group was 5.2% at one year versus 1.7% in controls but this did not reach statistical significance (HR 1.9; p = 0.33). Compared with controls, there was no significant difference in rate of dislocation in patients without a sacral fusion. When the sacrum was involved, the rate of dislocation was significantly higher than in controls (HR 4.5; p = 0.03), with a trend to more dislocations in longer lumbosacral fusions. Patient demographics and surgical characteristics of THA (i.e. surgical approach and femoral head diameter) did not significantly impact risk of dislocation (p > 0.05). Significant radiological differences were measured in mean anterior pelvic tilt between the one-level lumbar fusion group (22°), the multiple-level fusion group (27°), and the sacral fusion group (32°; p < 0.01). Ten-year survival was 93% in the fusion group and 95% in controls (HR 1.2; p = 0.8). Conclusion Lumbosacral spinal fusions prior to THA increase the risk of dislocation within the first six months. Fusions involving the sacrum with multiple levels of lumbar involvement notably increased the risk of postoperative dislocation compared with a control group and other lumbar fusions. Surgeons should take care with component positioning and may consider higher stability implants in this high-risk cohort.
Risk of hip fracture in patients on hemodialysis versus peritoneal dialysis: A meta‐analysis of observational studies
Wijarnpreecha, Karn , Cheungpasitporn, Wisit , Kaewput, Wisit , Ungprasert, Patompong , Cheungpasitporn, Wisit , Kaewput, Wisit , Wijarnpreecha, Karn , Boonpheng, Boonphiphop , Thongprayoon, Charat , Mao, Michael A.

Mayo Clinic

Journal of Evidence-Based Medicine | January 31, 2019 | Volume: 12 | Issue: 2 | Pages: 98-104

10.1111/jebm.12341 | PMID 30701673 Get It

AbstractBackgroundBone and mineral metabolism disorders are common among end‐stage renal disease (ESRD) patients, which could lead to hip fracture. It is unclear whether the hip fracture risk is different among patients on hemodialysis (HD) versus peritoneal dialysis (PD). This meta‐analysis was conducted to evaluate the hip fracture risk in ESRD patients on HD, when compared to PD.MethodsA literature review was conducted in EMBASE, MEDLINE, and Cochrane databases through January 31, 2018 to identify studies that appraised the rate or risk of hip fracture among patients on HD, when compared to PD. Effect estimates from the individual studies were derived and consolidated utilizing random‐effect, generic inverse variance approach of DerSimonian and Laird.ResultsFive cohort studies with 1 276 677 ESRD patients were enrolled. HD status was associated with a significantly higher risk of hip fracture with the pooled odds ratio (OR) of 1.61 (95% confidence interval [CI] 1.50‐1.73, I2 = 10.0%), compared with PD. When the analysis was limited to studies with confounder‐adjusted analysis, the pooled OR of hip fracture among HD patients was 1.57 (95% CI 1.43‐1.72, I2 = 13.6%). Funnel plots and Egger's regression test demonstrated no significant publication bias in our meta‐analysis.ConclusionsAmong ESRD patients, HD status is associated with a 61% higher risk of hip fracture compared to PD.